Nedocromil NEW
| Price | $64 | $97 | $213 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: Nedocromil | CAS No.: 69049-73-6 |
| Purity: 97.34% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | Nedocromil |
| Description | Nedocromil (FPL 59002) inhibits the action or formation of multiple mediators. Which including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2). |
| In vitro | Nedocromil suppresses the release of histamine, LTC4, and PGD2 from mast cells challenged with antigen with IC30 values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively. It also has anti-human IgE with IC30 values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively[1]. |
| In vivo | Nedocromil can obviously improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function. Nedocromil-treated diabetic mice display obviously improved heart function compared with controls. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 1 mg/mL (2.69 mM), Sonication is recommended. |
| Keywords | ProstaglandinReceptor | Prostaglandin Receptor | prostaglandin D2 receptor | PGD2 | Nedocromil | LTC4 | LeukotrieneReceptor | Leukotriene Receptor | leukotriene C4 (LTC4) | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | Histamine | FPL-59002 | FPL59002 |
| Inhibitors Related | Undecane | Tranilast | Meclizine dihydrochloride | Famotidine | Rutin | Sodium butanoate | Alginic acid | Rebamipide | Mianserin hydrochloride | Trazodone hydrochloride | p-Hydroxycinnamic acid | Doxepin hydrochloride |
| Related Compound Libraries | Histamine & Melatonin Receptor-Targeted Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-12-12 | ||
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 | |
| $150.00 |
Wuhan Nutra Biotechnology Co.,Ltd
|
2024-11-01 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY